2
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
6
Astrocytoma
4
Oligodendroglioma
2
Recurrence
1
Pathologic Processes
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Follicular
1
Healthy Adult Participants
1
Disease Attributes
1
Brain Neoplasms
1
Interventions
pembrolizumab
3
Pemetrexed
2
Cholecalciferol
2
vorasidenib
1
relacorilant
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
bosutinib
1
Trastuzumab
1
Sunitinib
1
Morphine
1
Methadone
1
MRX-2843
1
Letrozole
1
Imatinib Mesylate
1
Electrochemotherapy
1
Control Groups
1
Clomiphene
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Bevacizumab
1
Azacitidine
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing